Glenmark Pharma may touch Rs 658, says Sriram Rathi

Sriram Rathi of Anand Rathi told CNBC-TV18, "For Glenmark Pharma we are expecting EBITDA margin of around 20 percent which is flattish compared to the previous year and profit of around Rs 163 crore, which is double digit growth from the profit side."

"From longer term perspective we remain positive on Glenmark because US and India are doing consistently well and we expect that to continue. Howver, Latin America as well as semi regulated markets maybe subdued this quarter mainly because of the high base, but from longer term perspective we remain positive on the stock and target is Rs 658," he added.